Amneal Pharmaceuticals price to sales ratio AMRX

Market value divided by revenue over the last twelve months, since 2019.

Today, Oct 23, 2026: 2.1×
8-year median: 0.8×
Against its 8-year history: 97th; percentile: 0 is its lowest day, 100 its highest
8-year range: 0.2× to 2.5×
Peer median: 8.5×

Amneal Pharmaceuticals' price to sales ratio is 2.1× as of Oct 23, 2026.

That is above its 8-year median of 0.8×, higher than on 97% of days in the last 8 years.

Over that time it ranged from 0.2× in Mar 2023 to 2.5× in Mar 2019.

The median for 10 large drugmakers of a similar size is 8.5×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	2.1×	1.2×	2.1×
2025	1.4×	0.8×	1.4×
2024	0.9×	0.7×	1.0×
2023	0.8×	0.2×	0.8×
2022	0.3×	0.3×	0.7×
2021	0.7×	0.6×	1.1×
2020	0.7×	0.5×	0.9×
2019	0.8×	0.4×	2.5×

Against its peers

Companies in Drug Manufacturers - General nearest Amneal Pharmaceuticals' size, closest first, today.

Company	Price to sales ratio
AMRXAmneal Pharmaceuticals	2.1×
LGNDLigand Pharmaceuticals	20.8×
KNSAKiniksa Pharmaceuticals International	7.1×
ALKSAlkermes plc.	4.4×
TGTXTG Therapeutics	10.4×
PTGXProtagonist Therapeutics	31.8×
CORTCorcept Therapeutics	11.2×
INDVIndivior Pharmaceuticals	3.1×
ARQTArcutis Biotherapeutics	8.5×
BMRNBiomarin Pharmaceutical	3.2×
LQDALiquidia	8.5×
Peer median	8.5×

Where Amneal Pharmaceuticals ranks

#44of 157Large drugmakers with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Amneal Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.